智史 阪上

Dr. 智史 阪上

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Sinusitis
Verified
Journal Article
Open access
PDF file
YYyasutaka yun
yasutaka yun
MYMasao Yagi
Masao Yagi
智阪智史 阪上
智史 阪上
SSShunsuuke Sawada
Shunsuuke Sawada
YKYuka Kojima
Yuka Kojima
HIHiroshi Iwai
Hiroshi Iwai
Odontogenic maxillary sinusitis (OMS) is a disease in which inflammation from the teeth extend into the maxillary sinus, causing symptoms of unilateral sinusitis. OMS can recur, with some being resistant to antibiotics. In intractable cases, exodontia and endoscopic sinus surgery (ESS) are necessary treatments. Here we report our analysis on the indications for surgical intervention in cases diagnosed with and treated as OMS. We retrospectively examined 186 patients who were diagnosed with sinusitis on a computed tomography (CT) scan. For cases diagnosed with OMS, the site of the causative tooth and the presence or absence of oroantral fistula to the maxillary sinus was examined. In addition, we analyzed the therapeutic efficacy of the initial treatment of antibiotics, and what the indications were for ESS. Among the patients examined, OMS was diagnosed in 44 cases (23.6%). In 14 out of 20 cases that underwent a post-medical treatment CT scan, OMS found to be treatment-resistant. Of these 14 cases, 12 (88%) had oroantral fistulae to the maxillary sinus. In all cases where exodontia, fistula closure surgery, and endoscopic sinus surgery (ESS) were performed, the fistula disappeared and the shadow of inflammation in the paranasal sinus improved. In OMS with oroantral fistula, ESS, exodontia, and fistula closure should be recommended over medication such as macrolide therapy.

29 August 2024 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
KYKazuki Yokoyama
Kazuki Yokoyama
KWKoichiro Wasano
Koichiro Wasano
KSKeita Sasaki
Keita Sasaki
RMRyunosuke Machida
Ryunosuke Machida
MNMitsuhiko Nakahira
Mitsuhiko Nakahira
AHAkihiro Homma
Akihiro Homma
Background: Over the last decade, novel anticancer drugs have improved the prognosis for recurrent or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN). However, this has increased healthcare expenditures and placed a heavy burden on patients and society. This study investigated the frequency of use and costs of select palliative chemotherapy regimens in Japan. Methods: From July 2021 to June 2022 in 54 healthcare facilities, we gathered data of patients diagnosed with RM-SCCHN and who had started first-line palliative chemotherapy with one of eight commonly used regimens. Patients with nasopharyngeal carcinomas were excluded. The number of patients receiving each regimen and the costs of each regimen for the first month and per year were tallied. Results: The sample comprised 907 patients (674 were < 75 years old, 233 were ≥ 75 years old). 330 (36.4%) received Pembrolizumab monotherapy, and 202 (22.3%) received Nivolumab monotherapy. Over 90% of patients were treated with immune checkpoint inhibitors as monotherapy or in combination with chemotherapy. Treatment regimens’ first-month costs were 612 851–849 241 Japanese yen (JPY). The cost of standard palliative chemotherapy until 2012 was about 20 000 JPY per month. The incremental cost over the past decade is approximately 600 000–800 000 JPY per month, a 30- to 40-fold increase in the cost of palliative chemotherapy for RM-SCCHN. Conclusion: First-line palliative chemotherapy for RM-SCCHN exceeds 600 000 JPY monthly. Over the last decade, the prognosis for RM-SCCHN has improved, but the costs of palliative chemotherapy have surged, placing a heavy burden on patients and society.

26 December 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MYMasao Yagi
Masao Yagi
智阪智史 阪上
智史 阪上
MSMinaki Shimizu
Minaki Shimizu
YOYuhei Ogino
Yuhei Ogino
MMMizuki Morita
Mizuki Morita
HIHiroshi Iwai
Hiroshi Iwai
Background/Objectives: Parotid surgery is generally performed with the naked eye or using surgical loupes. However, this approach has technical disadvantages. Therefore, this study aimed to compare the use of an exoscope with that of loupe for parotidectomies. Methods: A retrospective review of patients who underwent partial parotidectomies for parotid tumors was conducted. We examined the approach (anterograde/retrograde), tumor localization (superficial/deep), operative time, volume of intraoperative blood loss, and postoperative complications occurring within 6 months. Results: Overall, 174 patients underwent parotidectomies (90 in the exoscope group, 84 in the loupe group). In parotidectomies using the anterograde approach, the exoscope group had significantly fewer reports of facial nerve palsy than the loupe group. Parotidectomy-related complications other than facial palsy were significantly fewer in the exoscope group. However, the operation time was significantly longer in the exoscope group than in the loupe group. Conclusions: An ORBEYETM exoscope provides a magnified view of the surgical field, leading to more accurate operations in parotid surgery and potentially fewer complications.

10 July 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
BSBoku Shogen
Boku Shogen
TITatsuki Ikoma
Tatsuki Ikoma
TYTomoyo Yasuda
Tomoyo Yasuda
Nobuhiro ShibataNobuhiro Shibata
Nobuhiro Shibata
智阪智史 阪上
智史 阪上
MKMasashi Kanai
Masashi Kanai
Background Recent studies have suggested a correlation between ABO blood type and the effectiveness of immune checkpoint inhibitors. However, the relationship between ABO blood type and response to pembrolizumab monotherapy as first-line treatment for squamous cell carcinoma of the head and neck (SCCHN) remains unclear. Method We retrospectively analyzed the patients who were treated with pembrolizumab as the first-line treatment for locally advanced, recurrent, or metastatic SCCHN between May 2020 and September 2024. Result A total of 38 cases were analysed in this study. The ABO blood types of patients were as follows: 15 (39.5%) were type A, 9 (23.7%) were type B, 3 (7.9%) were type AB, and 11 (28.9%) were type O. Median Overall survival (OS) by blood type was 28.9 months for type A, 7.8 months for type B, 45.6 months for type O, and 21.4 months for type AB. The OS of B antigen-positive group (B group; B or AB) was significantly poorer than that of B antigen-negative group (non-B group; A or O) (7.8 months [95% CI, 3.0-16.4] vs. 28.9 months [95% CI, 10.7–45.6], p = 0.0022). Progression-free survival (PFS) was 2.6 (95% CI, 1.2–7.6) months vs. 7.2 (95% CI, 3.5–24.1) months (p = 0.06), overall response rate (ORR) was 25.0 vs. 46.2% (p = 0.29) and disease control rate (DCR) was 41.7 vs. 76.9% (p = 0.06), respectively. Conclusion In this cohort, the presence of B antigen provides a significant disadvantage in terms of survival in patients using pembrolizumab for SCCHN.

1 July 2024 in OTO Open
Verified
Journal Article
Open access
智阪智史 阪上
智史 阪上
YNYuri Noda
Yuri Noda
NNNaohiro Nakamura
Naohiro Nakamura
KSKensuke Suzuki
Kensuke Suzuki
TFTakuo Fujisawa
Takuo Fujisawa
HIHiroshi Iwai
Hiroshi Iwai
Objective: This study aimed to investigate the utility of minor salivary glands in the hypopharynx as novel indicators for safe resection of superficial hypopharyngeal carcinomas with fewer complications.Study Design: Cadaveric study.Setting: Cadavers were stored in the pathology laboratory at Kansai Medical University.Methods: Twenty‐three cadaveric specimens were examined for minor salivary glands in the pyriform sinus, posterior wall, and postcricoid regions of the hypopharynx. Their count, size, and depth were assessed. Resected specimens from 5 consecutive patients with superficial hypopharyngeal carcinomas were pathologically analyzed to determine the positional relationship between cancer and minor salivary glands.Results: Minor salivary glands were present in more than 70% of patients in each region during autopsy, with the postcricoid region having a larger count and size. The glands were universally present, regardless of sex, height, or body mass index. Minor salivary glands in the pyriform sinus and postcricoid region were present at a depth of 30% from the bottom of the submucosal layer, whereas those in the posterior wall were present in the shallow muscularis. During surgery, endoscopic findings revealed minor salivary glands as small white nodules in the submucosal layer. Pathological examination of the resected specimen confirmed that the white nodule was a minor salivary gland. In addition, tumor position in relation to minor salivary glands provided an adequate margin for resection.Conclusion: Minor salivary glands may serve as reliable indicators for determining adequate deep safety margins during surgery for superficial hypopharyngeal carcinoma.

2 September 2025 in Acta Oto-Laryngologica Case Reports
Verified
Journal Article
Open access
智阪智史 阪上
智史 阪上
NNNaohiro Nakamura
Naohiro Nakamura
KSKensuke Suzuki
Kensuke Suzuki
TFTakuo Fujisawa
Takuo Fujisawa
MYMasao Yagi
Masao Yagi
HIHiroshi Iwai
Hiroshi Iwai